Discover groundbreaking results from the lidERA study, showcasing giredestrant's potential to redefine treatment for early breast cancer patients.
Erika Mayer, MD, MPH
Erika Mayer, MD, MPH, is a medical oncologist at Dana-Farber Cancer Institute.
Articles by Erika Mayer, MD, MPH